To contribute to an informed debate, the biotech trade group EuropaBio is launching a new brochure acknowledging the complexity of biotechnology-derived medicines (which are also referred to as biological medicines) and the emergence in Europe of a new category of biotech medicines: biosimilars.
Following the definition of the European Medicines Agency and the establishment of a regulatory approval pathway, EuropaBio believes that, due to the unique nature of biological medicines and biosimilars, the latter should not be treated in the same way as a generic of a chemical medicine.
Since introducing the concept of biosimilars in its legislation in 2004, the European Union has been at the forefront of the development of a strong science-based regulatory pathway for biosimilars, providing patients with the assurance that these products are safe and successful. In the context of global economic and financial constraints, biosimilars may have an important role to play in fostering competition in the market place and thereby contributing to the sustainability of healthcare budgets and securing the necessary funds to pay for further innovation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze